Rivoirard Romain, Vallard Alexis, Boutet Claire, Falk Alexander Tuan, Garin Clemence, Adjabi Anissa, Hoarau Delphine, Forest Fabien, Fotso Marie-Jeannette, Rancoule Chloe, Magné Nicolas
Department of Medical Oncology, Lucien Neuwirth Institute of Cancerology, 42270 Saint Priest en Jarez, France.
Department of Radiotherapy, Lucien Neuwirth Institute of Cancerology, 42270 Saint Priest en Jarez, France.
Mol Clin Oncol. 2018 Jan;8(1):115-120. doi: 10.3892/mco.2017.1479. Epub 2017 Nov 2.
Glioblastoma is one of the most common types of primary brain tumor. In situations of local recurrence, physicians can suggest either specific palliative anticancer treatments (SPAT; surgery, chemotherapy, radiotherapy) or best supportive care (BSC). The objective of the present study was to identify clinical factors that may have influenced the continuation or cessation of SPAT during the final 3 months of life in patients with glioblastoma. In the present retrospective single-center study, all records of patients treated for glioblastoma, who succumbed to the disease between June 2006 and February 2014, were assessed. All selected patients were divided into two groups, according to treatments received during the last 3 months of life: The SPAT and BSC groups. A total of 148 patients were included: 81 patients in the SPAT group (group A) and 67 patients in the BSC group (group B). A performance status equal to 0 was observed for 17.3% of patients in group A vs. 6% in group B. Following progression, chemotherapy was administered in 39.5% of cases in group A vs. 20.9% of cases in group B (P=0.0149). The mean number of lines of chemotherapy administered in group A was equal to 1.44±0.77 as compared with 1.06±0.67 in group B (P=0.0017). SPAT are utilized frequently among patients approaching mortality due to a glioblastoma. Certain factors, including the utilization of novel chemotherapy after the first progression or number of lines of chemotherapy previously administered, may have influenced physicians' decisions whether to continue with the SPAT or not.
胶质母细胞瘤是最常见的原发性脑肿瘤类型之一。在局部复发的情况下，医生可以建议采用特定的姑息性抗癌治疗（SPAT；手术、化疗、放疗）或最佳支持治疗（BSC）。本研究的目的是确定可能影响胶质母细胞瘤患者生命最后3个月期间SPAT持续或停止的临床因素。在本项回顾性单中心研究中，对2006年6月至2014年2月间因胶质母细胞瘤死亡的所有接受治疗患者的记录进行了评估。根据生命最后3个月接受的治疗，将所有入选患者分为两组：SPAT组和BSC组。共纳入148例患者：SPAT组（A组）81例患者，BSC组（B组）67例患者。A组17.3%的患者表现状态为0，而B组为6%。病情进展后，A组39.5%的病例接受了化疗，而B组为20.9%（P = 0.0149）。A组化疗的平均疗程数为1.44±0.77，而B组为1.06±0.67（P = 0.0017）。在因胶质母细胞瘤接近死亡的患者中，SPAT的使用频率较高。某些因素，包括首次进展后新型化疗的使用或先前接受化疗的疗程数，可能影响了医生是否继续进行SPAT的决定。
